BRAIN on growth track in the first half-year 2016/17
B.R.A.I.N. Biotechnology Research and Information Network AG published its financial results for the first half of fiscal year 2016/17.
Accordingly, during the reporting period from October 1, 2016, to March 31, 2017, the BRAIN Group grew its total operating performance by 3 percent from € 13.0 million to € 13.3 million. This development was driven mainly by the strong growth of the BioScience segment in the second quarter.
At the same time, revenues of BRAIN Group increased by 9 percent from € 11.2 million to € 12.1 million. The half-year EBIT was down from € -5.3 million to € -5.6 million mostly due to first quarter special items with no impact on liquidity. The BioIndustrial segment generated a positive EBIT contribution of € 0.2 million.
The operating cash flow developed positively, amounting to € -2.3 million compared to € -4.6 million in the previous year period.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Dess-Martin_periodinane
Atkins_Nutritional_Approach
Category:Endocannabinoid_reuptake_inhibitors
Nickel(II)_sulfate
Adolescent Body Mass Index (BMI) can predict early occurence of diabetes and heart disease in adulthood - New England Journal of Medicine Study Shows that BMI at Adolescence in the Normal Range Can Nevertheless Predict Risk of Early Type 2 Diabetes and Heart Disease in a Differential Manner
Algeta completes enrolment of 900 patients into phase III ALSYMPCA trial with Alpharadin - Primary endpoint is overall survival in castration-resistant prostate cancer (CRPC) patients with bone metastases
